Free tool
FAERS Monitor: Clarinex
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021563 or its brand name (Clarinex, Desloratadine). Reports on generic versions are filed under their own applications.
Reports
10,834
Serious
8,441
78% of reports
Hospitalization
4,109
Death reported
608
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective630
- fatigue629
- nausea607
- dyspnoea544
- headache485
- diarrhoea471
- dizziness458
- pruritus445
- vomiting417
- rash396
- off label use357
- pyrexia333
- pain332
- asthenia327
- arthralgia321
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 467 |
| 2005 | 347 |
| 2006 | 311 |
| 2007 | 355 |
| 2008 | 292 |
| 2009 | 283 |
| 2010 | 341 |
| 2011 | 444 |
| 2012 | 459 |
| 2013 | 255 |
| 2014 | 246 |
| 2015 | 425 |
| 2016 | 480 |
| 2017 | 401 |
| 2018 | 628 |
| 2019 | 738 |
| 2020 | 653 |
| 2021 | 516 |
| 2022 | 683 |
| 2023 | 601 |
| 2024 | 764 |
| 2025 | 603 |
| 2026 | 542 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,325 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pruritusSignal | 445 | 2.2 | 2.1 | 313 |
| pyrexia | 333 | 1.9 | 1.7 | 136 |
| dyspnoea | 544 | 1.9 | 1.7 | 224 |
| dizziness | 458 | 1.8 | 1.6 | 160 |
| rash | 396 | 1.8 | 1.6 | 133 |
| vomiting | 417 | 1.7 | 1.6 | 128 |
| asthenia | 327 | 1.7 | 1.5 | 93 |
| fatigue | 629 | 1.6 | 1.5 | 134 |
| headache | 485 | 1.5 | 1.4 | 83 |
| arthralgia | 321 | 1.5 | 1.3 | 54 |
| nausea | 607 | 1.5 | 1.4 | 101 |
| diarrhoea | 471 | 1.4 | 1.3 | 59 |
| pain | 332 | 1.0 | 0.9 | 1 |
| drug ineffective | 630 | 0.9 | 0.9 | 4 |
| off label use | 357 | 0.8 | 0.7 | 20 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.